StockNews.AI
MRKR
StockNews.AI
92 days

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

1. Dr. Juan Vera will discuss MAR-T cell therapy on May 28, 2025. 2. Event will focus on CAR-T cell expectations versus reality. 3. Panel features leading experts in cancer and cell therapy. 4. MAR-T cells aim to address CAR-T therapy shortcomings. 5. Marker Therapeutics prioritizes operational excellence and funding.

6m saved
Insight
Article

FAQ

Why Bullish?

The presence of Dr. Vera and expert panel showcases MRKR's innovation, potentially attracting investor interest, similar to past biotech events that boosted share prices post-announcement.

How important is it?

The discussion around MAR-T cell therapy positions MRKR favorably in the competitive immuno-oncology field, especially with expert validations enhancing perceived value.

Why Short Term?

The webcast is imminent, likely generating immediate investor interest and potentially affecting stock prices shortly afterward, reflecting movements seen in other biotech discussions.

Related Companies

KITEGILDBMYNVSCARA
HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled “Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?”. The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, followed by a roundtable discussion. Dr. Vera will present Marker’s MAR-T cell therapy platform as a novel, non-engineered multi-antigen approach designed to address the shortcomings associated with CAR-T cell therapies. Panelists include renowned experts in the cancer field, whose contributions have significantly shaped the field of immuno-oncology: Helen Heslop, M.D., DSC, Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s HospitalMalcolm Brenner, M.D., Ph.D., Founding Director of the Center for Cell and Gene Therapy and Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular GeneticsManali Kamdar, M.D., Associate Professor, University of ColoradoGeoffrey Shouse, D.O., Ph.D., Assistant Professor, City of HopeJuan Vera, M.D., President and Chief Executive Officer, Marker Therapeutics The extensive knowledge and unique perspectives of the panelists promises a profound and impactful discussion. Virtual Webcast Agenda – May 28, 2025 at 11:00 am – 12:00 pm E.D.T: 11:00 – 11:05 amIntroduction Sara Demy, Founder & CEO, Demy-ColtonSteve Brozak, President and Co-founder, WBB Securities11:05 – 11:10 amUnderstanding the Shortcomings of CAR-T Therapy Helen Heslop, MD, Baylor College of Medicine11:10 – 11:15 amOvercoming the Current Limitations of CAR-T Therapy Malcolm Brenner, MD, PhD, Baylor College of Medicine11:15 – 11:20 amMAR-T Cells as Novel Approach to Address Unmet Needs Juan Vera, MD, Marker Therapeutics11:20 – 11:50 amRoundtable DiscussionModerator:Richard Marfuggi, MD, DMH (Medical Director of the WBB Research Institute)Panelists:Geoffrey Shouse, DO, PhD (City of Hoppe)Helen Heslop, MD, DSC (Baylor College of Medicine)Juan Vera, MD (Marker Therapeutics)Malcolm Brenner, MD, PhD (Baylor College of Medicine)Manali Kamdar, MD (University of Colorado)11:50 – 12:00 pmQ&A The roundtable discussion will be accessible online, allowing participants worldwide to join and take part in this crucial dialogue. To attend the roundtable discussion, please register at: https://virtualsalon.demy-colton.com/2025/05/07/seven-years-after-fda-approval-have-cd19-car-t-cells-met-expectations/ About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research. To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts. Media and Investor ContactMarker Therapeutics, Inc.+1 (713) 400-6400investor.relations@markertherapeutics.com

Related News